RBX 2660

Drug Profile

RBX 2660

Alternative Names: Microbiota restoration therapy - Rebiotix; Microbiota suspension - Rebiotix; RBX-2660

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rebiotix
  • Class Antibacterials; Antidiarrhoeals; Antiulcers; Hepatoprotectants; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Clostridium infections
  • Phase I Hepatic encephalopathy; Urinary tract infections; Vancomycin-resistant enterococcal infections
  • Phase 0 Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 31 Jul 2017 Phase-III clinical trials in Clostridium infections (Recurrent, Prevention) in USA (Rectal) (NCT03244644)
  • 18 Jul 2017 Phase-I clinical trials in Hepatic encephalopathy in USA (Rectal) (Rebiotix pipeline, July 2017)
  • 18 Jul 2017 Phase-I clinical trials in Urinary tract infections in USA (Rectal) (Rebiotix pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top